Use of novel and conventional biomarkers for management of patients with heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 6, 2011, Pages 475-488

  Schlendorf, Kelly H ^a   Kasper, Edward K ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; ERYTHROPOIETIN; GALECTIN 3; MICRORNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; PROTEIN PRECURSOR; SYNDECAN 4; TROPONIN; UNCLASSIFIED DRUG; UREA;

ARTICLE; CLINICAL ASSESSMENT; FOLLOW UP; HEART FAILURE; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PROGNOSIS; UREA NITROGEN BLOOD LEVEL;

EID: 81155123008     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0150-9     Document Type: Article

References (44)

1. VL Roger AS Go DM Lloyd-Jones, et al. 2011 Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circ 123 4 e18 e209 10.1161/CIR.0b013e3182009701
2. JS Ross J Chen Z Lin, et al. 2010 Recent national trends in readmission rates after heart failure hospitalization Circ Heart Fail 3 97 103 19903931 10.1161/CIRCHEARTFAILURE.109.885210
3. Medscape Reference on Heart Failure. Available at http://emedicine. medscape.com/article/163062-overview#a0156. Accessed May 2011.
4. NACB LMPG Committee Members GL Myers RH Christenson M Cushman, et al. 2009 National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease Clin Chem 55 2 378 384 19106185 1:CAS:528:DC%2BD1MXhvVWksLc%3D
5. JL Januzzi Jr CA Camargo S Anwaruddin, et al. 2005 The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study Am J Cardiol 95 8 948 954 15820160 10.1016/j.amjcard.2004.12.032 1:CAS:528: DC%2BD2MXjtlWjurs%3D (Pubitemid 40487743)
6. GC Fonarow WF Peacock CO Phillips, et al. 2007 Admission B-type natriuretic peptide levels and in- hospital mortality in acute decompensated heart failure J Am Coll Cardiol 49 19 1943 1950 17498579 10.1016/j.jacc.2007.02. 037 1:CAS:528:DC%2BD2sXlt1amtLw%3D (Pubitemid 46694287)
7. M Behnes M Breukmann P Ahmad-Nejad, et al. 2009 Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema Intl J Card 135 165 174 10.1016/j.ijcard.2008.03.045
8. GW Moe J Howlett J Januzzi, et al. 2007 N-Terminal pro-B-type atriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study Circ 115 3103 3110 10.1161/CIRCULATIONAHA.106.666255 1:CAS:528:DC%2BD2sXmtlGks7Y%3D (Pubitemid 46956499)
9. M Jessup WT Abraham DE Casey, et al. 2009 2009 Focused Update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the international society for heart and lung transplantation J Am Coll Cardiol 53 15 1343 1382 10.1016/j.jacc.2008.11.009
10. JA Doust E Pietrzak A Dobson, et al. 2005 How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ 330 625 15774989 10.1136/bmj.330.7492.625 1:CAS:528:DC%2BD2MXjtlaht74%3D
11. P Bettencourt A Azevedo J Pimenta, et al. 2004 N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circ 110 2168 2174 10.1161/01.CIR.0000144310.04433.BE 1:CAS:528:DC%2BD2cXotFGksLk%3D (Pubitemid 39372496)
12. A Cohen-Solal D Logeart B Huang, et al. 2009 Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure J Am Coll Cardiol 53 2343 2348 19539144 10.1016/j.jacc.2009.02.058 1:CAS:528:DC%2BD1MXovFShtLo%3D
13. H Michtalik Y Hsin-Chieh CY Campbell, et al. 2011 Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure Am J Cardiol 107 1191 1195 21296322 10.1016/j.amjcard.2010.12.018 1:CAS:528:DC%2BC3MXkt1ahurc%3D
14. Felker GM. Admission, discharge, or change in BNP and long-term mortality: Data from OPTIMIZE-HF linked with Medicare claims. Presented at the Heart Failure Society of America 2010 Scientific Meeting. San Diego, CA; September 14, 2010.
15. H Kim JL Januzzi 2010 Biomarkers in the management of heart failure Curr Treat Options Cardio Med 12 519 531 10.1007/s11936-010-0096-3 This review provides a thorough overview of the biology and mechanisms of action of the natriuretic peptides, as well as further perspective on the use of these biomarkers to guide HF management.
16. MR Shah 2006 STARBRITE: A randomized pilot trial of BNP-guided therapy in patients with advanced heart failure Circ 114 II-528
17. P Jourdain G Jondeau F Funck, et al. 2007 Plama brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study J Am Coll Cardiol 49 1733 1739 17448376 10.1016/j.jacc.2006. 10.081 1:CAS:528:DC%2BD2sXksFWqtbg%3D (Pubitemid 46589928)
18. M Pfisterer P Buser H Rickli, et al. 2009 BNP-guided versus symptom-guided heart failure therapy: The trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial JAMA 301 4 383 392 19176440 10.1001/jama.2009.2 1:CAS:528:DC%2BD1MXhtlWgsbw%3D
19. JG Lainchbury RW Troughton KM Strangman, et al. 2010 N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED trial J Am Coll Cardiol 55 53 60 10.1016/j.jacc.2009.02.095 1:CAS:528:DC%2BC3cXhvVyhtbk%3D
20. LWM Eurlings PEJ van Pol WE Kok, et al. 2010 Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: Results of the PRIMA (Can pro-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure morbidity and mortality?) study J Am Coll Cardiol 56 2090 2100 21144969 10.1016/j.jacc.2010.07.030 1:CAS:528:DC%2BC3MXnvV2ltw%3D%3D
21. R Berger D Moertl S Peter, et al. 2010 N-Terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: A 3-arm, prospective, randomized pilot study J Am Coll Cardiol 55 645 653 20170790 10.1016/j.jacc.2009.08.078 1:CAS:528:DC%2BC3cXjslKgsrw%3D
22. H Persson H Erntell B Eriksson, et al. 2010 Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure) Eur J of Heart Fail 12 1300 1308 10.1093/eurjhf/hfq169 1:CAS:528:DC%2BC3cXhsFShtbbN
23. Januzzi J. Benefits of natriuretic peptide guided heart failure therapy for patients with chronic left ventricular systolic dysfunction: Primary Results of the pro-BNP outpatient tailored chronic heart failure therapy (PROTECT) study. Presented at the American Heart Association 2010 scientific sessions. Chicago, IL; November 15, 2010. Presented at the 2010 American Heart Association meeting, PROTECT demonstrated a reduction in cardiovascular events among HF patients receiving hormone-guided therapy.
24. Schou M, et al. NT-proBNP stratified long-term follow-up in outpatient heart failure clinics: A prospective randomized multicenter trial in the Danish heart failure clinics network. Presented at ACC. New Orleans, LA; April 5, 2011. Presented at the 2011 American College of Cardiology meeting, NorthStar was the largest multicenter trial of NT-proBNP-guided therapy to date, finding no significant benefit to a hormone-guided strategy over and above strategies guided by clinical assessment alone.
25. E Missov C Calzolari B Pau 1997 (1997) Circulating cardiac troponin I in severe congestive heart failure Circ 96 2953 2958 1:STN:280: DyaK1c%2FksF2huw%3D%3D (Pubitemid 27500095)
26. A Bass JH Patterson KF Adams 2010 Perspective on the clinical application of troponin in heart failure and states of cardiac injury Heart Fail Rev 15 305 317 19347578 10.1007/s10741-008-9124-8 1:CAS:528:DC%2BC3cXns1Clur0%3D
27. GC Fonarow WF Peacock TB Horwich, et al. 2008 Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE Am J Cardiol 101 231 237 18178412 10.1016/j.amjcard.2007.07.066 1:CAS:528:DC%2BD1cXisFGmtg%3D%3D
28. C Kawahara T Tsutamoto K Nishiyama, et al. 2011 Prognostic role of high sensitivity cardiac troponin T in patients with non-ischemic dilated cardiomyopathy Circ J 75 656 661 21178288 10.1253/circj.CJ-10-0837
29. T Kubo H Kitaoka M Okawa, et al. 2011 Combined measurements of cardiac troponin I and brain natriuretic peptide are sseful for predicting adverse outcomes in hypertrophic cardiomyopathy Circ J 75 919 926 21304210 10.1253/circj.CJ-10-0782
30. JK Ghali IS Anand WT Abraham, et al. 2008 Randomized double-blind trial of darbopoeitin alfa in patients with symptomatic heart failure and anemia Circ 117 526 535 10.1161/CIRCULATIONAHA.107.698514 1:CAS:528:DC%2BD1cXotlCrtw%3D%3D
31. AMS Belonje AA Voors P van der Meer, et al. 2010 Endogenous erythropoietin and heart failure Circ 121 245 251 10.1161/CIRCULATIONAHA.108. 844662 1:CAS:528:DC%2BC3cXktVCnsw%3D%3D
32. A Kazory 2010 Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure Am J Cardiol 106 694 700 20723648 10.1016/j.amjcard.2010.04.024 1:CAS:528:DC%2BC3cXhtVGmt7vJ
33. I Gotsman D Zwas D Planer, et al. 2010 The significance of serum urea and renal function in patients with heart failure Medicine 89 197 203 20616658 10.1097/MD.0b013e3181e893ee 1:CAS:528:DC%2BC3cXosFGis7s%3D
34. JM Testani TP Cappola CM Brensinger, et al. 2011 Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure J Am Coll Cardiol 58 375 382 21757114 10.1016/j.jacc.2011.01.052 1:CAS:528:DC%2BC3MXhtVKksrnI This study suggests that the risk of adverse outcomes in HF patients receiving loop diuretic doses in excess of 160 mg/day is largely depending on serum concentrations of blood urea nitrogen, with higher serum levels a potential marker for worse outcomes.
35. A Maisell C Mueller R Nowak, et al. 2010 Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea. Results from the BACH (Biomarkers in Acute Heart Failure) Trial J Am Coll Cardiol 55 2062 2076 10.1016/j.jacc.2010.02.025 In the BACH trial, two stable analytes of adrenomedullin were demonstrated to be useful in accurately diagnosing acute HF and predicting survival among hospitalized HF patients.
36. A Maisell C Mueller R Nowak, et al. 2011 Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea. Results from the BACH (Biomarkers in Acute Heart Failure) Trial J Am Coll Cardiol 58 1057 1067 10.1016/j.jacc.2011.07.032
37. AA Voors S von Haehling SD Anker, et al. 2009 C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study Eur Heart J 30 1187 1194 19346228 10.1093/eurheartj/ehp098 1:CAS:528:DC%2BD1MXmtFCisr0%3D
38. S Neuhold M Huelsmann G Strunk, et al. 2008 Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure J Am Coll Cardiol 52 266 272 18634981 10.1016/j.jacc.2008.03.050 1:CAS:528:DC%2BD1cXoslWmtL0%3D (Pubitemid 351957847)
39. RR Van Kimmenade JL Januzzi Jr PT Ellinor, et al. 2006 Utility of amino-terminal probrain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 1217 24 16979009 10.1016/j.jacc.2006.03.061 (Pubitemid 44345127)
40. DJA Lok P van der Meer 2010 Bruggink-André de la Porte PW, et al.: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 323 8 20130888 10.1007/s00392-010-0125-y 1:CAS:528:DC%2BC3cXlt1Wqs74%3D
41. R De Boer DJA Lok R Jaarsma, et al. 2011 Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 60 68 21189092 10.3109/07853890.2010.538080 Galectin-3 is among the potential candidate biomarkers in HF patients with preserved ejection fraction.
42. B Ky B French K McCloskey, et al. 2011 High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ Heart Fail 4 2 180 187 21178018 10.1161/CIRCHEARTFAILURE.110.958223
43. Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2011, [Epub ahead of print].
44. Takahashi R, Negishi K, Watanabe A, et al. Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J Cardiol 2011.